ReviewAdvanced drug delivery reviews2019
Molecular imaging of β-cells: diabetes and beyond.
Review in Advanced drug delivery reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Upconverting Nanoparticles for Bimodal Luminescence and Magnetic Resonance Imaging of Langerhans Islets.Small science · 2026Article
- β-cell dedifferentiation in type 2 diabetes: Interplay of metabolic stress, endoplasmic reticulum dysfunction, and forkhead box protein O1 inhibition.World journal of diabetes · 2025Article
- Relationship between imaging changes of the pancreas and islet beta-cell function.World journal of radiology · 2024Article
- Development of an ostrich-derived single-chain variable fragment (scFv) against PTPRN extracellular domain.Scientific reports · 2024Article
- Imaging in Type 1 Diabetes, Current Perspectives and Directions.Molecular imaging and biology · 2023Article
- Chitosan Derivative-Based Microspheres Loaded with Fibroblast Growth Factor for the Treatment of Diabetes.Polymers · 2023Article
- mActa biochimica et biophysica Sinica · 2023Review
- New Insights and Potential Therapeutic Interventions in Metabolic Diseases.International journal of molecular sciences · 2023Review
- Polymer-Based Nanostructures for Pancreatic Beta-Cell Imaging and Non-Invasive Treatment of Diabetes.Pharmaceutics · 2023Review
- Investigating the Expression and Function of the Glucose Transporter GLUT6 in Obesity.International journal of molecular sciences · 2022Article
- Identification and Validation of a New Peptide Targeting Pancreatic Beta Cells.Molecules (Basel, Switzerland) · 2022Article
- Imaging evaluation of the pancreas in diabetic patients.Abdominal radiology (New York) · 2022Review
- Interaction of Medicinal Plants and Their Active Constituents With Potassium Ion Channels: A Systematic Review.Frontiers in pharmacology · 2022Review
- PET Imaging of VMAT2 with the Novel Radioligand [ACS chemical neuroscience · 2021Article
- Dynamic PET imaging with ultra-low-activity ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- First clinical experience of 106 cm, long axial field-of-view (LAFOV) PET/CT: an elegant balance between standard axial (23 cm) and total-body (194 cm) systems.European journal of nuclear medicine and molecular imaging · 2021Article
- Targeting Small GTPases and Their Prenylation in Diabetes Mellitus.Journal of medicinal chemistry · 2021Review
- Islet Regeneration: Endogenous and Exogenous Approaches.International journal of molecular sciences · 2021Review
- Ramatroban-Based Analogues Containing Fluorine Group as PotentialMolecules (Basel, Switzerland) · 2021Review
- T Cell Protein Tyrosine Phosphatase in Glucose Metabolism.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Since diabetes is becoming a global epidemic, there is a great need to develop early β-cell specific diagnostic techniques for this disorder. There are two types of diabetes (i.e., type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM)). In T1DM, the destruction of pancreatic β-cells leads to reduced insulin production or even absolute insulin deficiency, which consequently results in hyperglycemia. Actually, a central issue in the pathophysiology of all types of diabetes is the relative reduction of β-cell mass (BCM) and/or impairment of the function of individual β-cells. In the past two decades, scientists have been trying to develop imaging techniques for noninvasive measurement of the viability and mass of pancreatic β-cells. Despite intense scientific efforts, only two tracers for positron emission tomography (PET) and one contrast agent for magnetic resonance (MR) imaging are currently under clinical evaluation. β-cell specific imaging probes may also allow us to precisely and specifically visualize transplanted β-cells and to improve transplantation outcomes, as transplantation of pancreatic islets has shown promise in treating T1DM. In addition, some of these probes can be applied to the preoperative detection of hidden insulinomas as well. In the present review, we primarily summarize potential tracers under development for imaging β-cells with a focus on tracers for PET, SPECT, MRI, and optical imaging. We will discuss the advantages and limitations of the various imaging probes and extend an outlook on future developments in the field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.